<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00972140</url>
  </required_header>
  <id_info>
    <org_study_id>RA-PR-3301-011-04</org_study_id>
    <nct_id>NCT00972140</nct_id>
  </id_info>
  <brief_title>Formoterol-HFA 3-month Study in Chronic Obstructive Pulmonary Disease (COPD) Patients</brief_title>
  <official_title>A 3-month, Double-blind, Double-dummy, Randomised, Multinational, Multicenter, 2-arm Parallel-group Study Comparing the Efficacy and Safety of Formoterol-HFA pMDI 12µg Twice Daily and Formoterol-DPI 12µg Twice Daily, in Patients With Stable Chronic Obstructive Pulmonary Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chiesi Farmaceutici S.p.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chiesi Farmaceutici S.p.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to demonstrate the clinical equivalence of formoterol-HFA pMDI&#xD;
      12µg/actuation administered twice daily to formoterol DPI 12µg/capsule delivered by the&#xD;
      Aerolizer inhaler and administered twice daily in patients with COPD.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Phase III, multicenter, multinational, double-blind, double-dummy, randomised, 2-arm&#xD;
      parallel-group, 3-month study in patients with stable COPD.&#xD;
&#xD;
      Comparison in terms of efficacy and safety of the two formulations of formoterol administered&#xD;
      as 24µg/day in a bid regimen&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2005</start_date>
  <completion_date type="Actual">October 2006</completion_date>
  <primary_completion_date type="Actual">April 2006</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>12-hour post-morning dose average FEV1 (area under the FEV1 versus time curve divided by 12 hours) after 12 weeks of treatment</measure>
    <time_frame>Every 6 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pulmonary Function tests :FEV1, FVC, symptom scores, COPD exacerbations, used of rescue</measure>
    <time_frame>Every 6 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">457</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <arm_group>
    <arm_group_label>Formoterol-HFA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Formoterol-HFA pMDI 12µg twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Formoterol-DPI</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Formoterol-DPI 12µg twice daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Formoterol</intervention_name>
    <description>Formoterol-HFA pMDI 12µg twice daily</description>
    <arm_group_label>Formoterol-HFA</arm_group_label>
    <other_name>Atimos</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Formoterol</intervention_name>
    <description>Formoterol-DPI 12 µg twice daily</description>
    <arm_group_label>Formoterol-DPI</arm_group_label>
    <other_name>Foradil</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male and female patients who gave written informed consent.&#xD;
&#xD;
          -  Diagnosis of stable COPD according to the recommendations of the -Diagnosis of stable&#xD;
             COPD according to the recommendations of the National Heart Lung and Blood Institute&#xD;
             (NHLBI) Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria,&#xD;
             Edition 2003&#xD;
&#xD;
          -  Age 40 years or older. Male and female patients who gave written informed consent&#xD;
&#xD;
          -  History of a progressive nature of symptoms and a complaint of dyspnoea at least on&#xD;
             exertion.&#xD;
&#xD;
          -  Current or previous smoker [in both cases with a cumulative exposure to cigarette&#xD;
             smoke of more than 20 pack-years&#xD;
&#xD;
          -  Pre-bronchodilator baseline 40% &gt; FEV1 &lt; 70% of the predicted normal value&#xD;
&#xD;
          -  Absolute value FEV1 &gt; 0.9 L.&#xD;
&#xD;
          -  FEV1/FVC &lt; 70% (ERS criteria for predicted normal value).&#xD;
&#xD;
          -  FEV1 reversibility test 30 minutes following inhalation of 400 μg of salbutamol pMDI&#xD;
&#xD;
          -  A cooperative attitude and ability to be trained to use correctly the pMDI and the&#xD;
             Aerolizer® inhaler&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Female subjects: pregnant, lactating mother or lack of efficient contraception in a&#xD;
             subject with childbearing potential (e.g. contraceptive methods other than oral&#xD;
             contraceptives, IUD, tubal ligature).&#xD;
&#xD;
          -  Current or past diagnosis of asthma.&#xD;
&#xD;
          -  History of allergic rhinitis or other atopic disease (e.g. eczema).&#xD;
&#xD;
          -  Largely reversible airflow obstruction.&#xD;
&#xD;
          -  Onset of obstructive symptoms early in life (i.e. childhood).&#xD;
&#xD;
          -  Variability of symptoms from day to day and frequent symptoms at night and early&#xD;
             morning.&#xD;
&#xD;
          -  A total blood eosinophil count higher than 500/μL.&#xD;
&#xD;
          -  Significant and unstable concomitant cardiovascular, renal, hepatic,&#xD;
             gastrointestinal,neurological, endocrine, metabolic, musculo-skeletal, neoplastic,&#xD;
             respiratory or other clinically significant disease&#xD;
&#xD;
          -  Clinical significant laboratory abnormalities indicating a significant or unstable&#xD;
             concomitant disease.&#xD;
&#xD;
          -  QTc interval (Bazett formula) higher than 460 msec&#xD;
&#xD;
          -  Total 24 hours respiratory symptom score (day-time and night-time) &gt; 2 on at least 4&#xD;
             consecutive days&#xD;
&#xD;
          -  Lower respiratory tract infection within one month before screening visit&#xD;
&#xD;
          -  Hospitalisation or emergency room treatment for an acute COPD exacerbation in the&#xD;
             month before screening visit&#xD;
&#xD;
          -  Long-term oxygen therapy.&#xD;
&#xD;
          -  Patients treated with oral or injectable corticosteroids and antibiotics for a COPD&#xD;
             exacerbation and/or a lower respiratory tract infection in the month preceding the&#xD;
             screening visit and during the run-in period of the study.&#xD;
&#xD;
          -  Patients treated with depot corticosteroids in the three months preceding the&#xD;
             screening visit and during the 14-week study period.&#xD;
&#xD;
          -  Changes in dose, schedule, formulation or product of an inhaled or nasal&#xD;
             corticosteroid and oral modified-release theophylline within one month of screening&#xD;
             visit and during the 14 week study period&#xD;
&#xD;
          -  Patients treated with inhaled long-acting β2-agonists during the 14-week study period.&#xD;
&#xD;
          -  Short-acting β2-agonists on regular use during the 14-week study period 8 hours&#xD;
             preceding the screening visit&#xD;
&#xD;
          -  Short-acting anticholinergic medications during the 14-week study period&#xD;
&#xD;
          -  Long-acting anticholinergic medications (e.g. tiotropium) during the 14-week study&#xD;
             period.&#xD;
&#xD;
          -  Inhaled fixed combinations of a short-acting β2-agonist and a short-acting&#xD;
             anticholinergic medication (e.g. Combivent) during the 14-week study period&#xD;
&#xD;
          -  Inhaled fixed combinations of an inhaled corticosteroid and a long-acting β2-agonist&#xD;
             (e.g.Seretide, Symbicort) during the 14-week study period.&#xD;
&#xD;
          -  Long-acting antihistamines (e.g. Astemizole, Terfenadine) in the three months&#xD;
             preceding the screening visit and during the 14-week study period.&#xD;
&#xD;
          -  Tricyclic antidepressants, monoamine oxidase inhibitors (MAOI) and other drugs known&#xD;
             to prolong the QTc interval during the 14-week study period.&#xD;
&#xD;
          -  β-blockers in the week preceding the screening visit and during the 14-week study&#xD;
             period.&#xD;
&#xD;
          -  Intolerance to inhaled β2-adrenergic agents.&#xD;
&#xD;
          -  History of intolerance or allergic reactions to any of the pMDI and DPI excipients.&#xD;
&#xD;
          -  Patients who had evidence of alcohol or substance abuse, not compliant with the study&#xD;
             protocol or not compliant with the study treatments.&#xD;
&#xD;
          -  Participation in another clinical trial with an investigational drug in the four weeks&#xD;
             preceding the screening visit&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Iwona Graelewska Rzymowska, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinic Pneumology and Allergology Lodz Poland</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Prof. Iwona Graelewska Rzymowska</name>
      <address>
        <city>Lodz</city>
        <state>Lódz</state>
        <zip>91-520</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <verification_date>December 2011</verification_date>
  <study_first_submitted>September 3, 2009</study_first_submitted>
  <study_first_submitted_qc>September 3, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 4, 2009</study_first_posted>
  <last_update_submitted>December 12, 2011</last_update_submitted>
  <last_update_submitted_qc>December 12, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 13, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Patients with stable COPD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Formoterol Fumarate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

